A Double Blind, 3rd Party Open, Placebo Controlled, Dose Escalating, Parallel Group Study To Investigate The Safety, Toleration And Pharmacokinetics Of Multiple Oral Doses Of PF-04531083 In Healthy Subjects.
Phase of Trial: Phase I
Latest Information Update: 18 Apr 2010
At a glance
- Drugs PF 4531083 (Primary)
- Indications Pain
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Pfizer
- 18 Apr 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 11 Feb 2010 Planned end date changed from 1 Jan 2010 to 1 Apr 2010 as reported by ClinicalTrials.gov.
- 09 Dec 2009 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.